Diabetes cure: USFDA approves Biocon#39;s long-acting insulin Semglee as first interchangeable biosimilar product

Diabetes cure: USFDA’s designation of Semglee (insulin glargine) as interchangeable with Lantus (insulin glargine of Sanofi) means that Semglee may now be substituted for the reference product at the pharmacy without the intervention of the prescriber.

from Moneycontrol Business News https://ift.tt/3f9mtIh